Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results. After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thoracic oncology Vol. 7; no. 11; p. 1713
Main Authors:	Gridelli, Cesare, de Marinis, Filippo, Pujol, Jean-Louis, Reck, Martin, Ramlau, Rodryg, Parente, Barbara, Pieters, Thierry, Middleton, Gary, Corral, Jesus, Winfree, Katherine, Melemed, Symantha, Zimmermann, Anna, John, William, Beyrer, Julie, Chouaki, Nadia, Visseren-Grul, Carla, Paz-Ares, Luis G
Format:	Journal Article
Language:	English
Published:	United States 01-11-2012
Subjects:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Cisplatin - administration & dosage Disease Management Double-Blind Method Female Follow-Up Studies Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Health Resources Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Neoplasm Staging Pemetrexed Prognosis Quality of Life Remission Induction Survival Rate
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!